Search or

𝛼SK

ENTITY

Abbisko Cayman (2256 HK)

23

Analysis

Health Care • China

Abbisko Cayman Limited operates as a biopharmaceutical company. The Company dedicated to the discovery and development of innovative and differentiated small molecule incology therapies. Abbisko Cayman provides services in China.

more

Refresh

Exchange Announcement • 01 Dec 2025 17:39

Voluntary Announcement - Ind Clearance From The Fda For Oral Small Molecule Kras G12d Inhibitor Absk141

Exchange Announcement • 17 Nov 2025 08:00

Voluntary Announcement - Abbisko Therapeutics Presents Longer-Term Efficacy And Safety Outcomes From Phase Iii Maneuver Study Of Pimicotinib At Ctos 2025 Annual Meeting

Exchange Announcement • 03 Nov 2025 08:00

Voluntary Announcement - Abbisko Therapeutics Completes First Patient Dosing In A Phase Ii Study Of Absk043, An Oral Small-Molecule Pd-L1 Inhibitor, In Combination With Glecirasib For The Treatment Of Nsclc

Exchange Announcement • 27 Oct 2025 08:00

Voluntary Announcement - Abbisko Therapeutics Presented Preclinical Findings On Novel Cdk4/2 Inhibitor And Smarca2 Protac Degrader At The 37th Aacr-Nci-Eortc Conference

Exchange Announcement • 20 Oct 2025 08:00

Voluntary Announcement - Abbisko Therapeutics Presents Longer-Term Efficacy And Safety Outcomes From Phase Iii Maneuver Trial Of Pimicotinib At Esmo 2025

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.59.7

x